Clinical Trial

Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy

Study acronym: INMUNOCELL
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2024 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). Recently, strategies based on immunotherapy adoptive cells (IAC) with anti-CMV Cytolitic T Lymphocytes (CMV-CTLs) has been incorporated to prevent or treat CMV after HSCT. The aim to study donor derived CMV-CTLs after haploidentical HSCT (HAPLO) as prophylaxis for CMV infection in transplant patients. CMV-CTLs will be administer at day 21 (+-7 days) post-HAPLO. CMV DNA levels with quantitative PCR will be weekly monitored.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-08-13; most recent amendment 2024-08-27.
Status change: Not Yet Recruiting → Recruiting 2022-05-05
Trial Details
NCT Number NCT04056533
Lead Sponsor Instituto de Investigación Marqués de Valdecilla
Conditions CMV
Enrollment 15 participants
Start Date 2022-03-26
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-28